BioCryst Pharmaceuticals BCRX Lease Liability Payments - Due Year Four
Lease Liability Payments - Due Year Four at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's lease liability payments - due year four.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's lease liability payments - due year four?
- BioCryst Pharmaceuticals (BCRX) reported lease liability payments - due year four of $1.59M in Q1 2026.
- How has BioCryst Pharmaceuticals's lease liability payments - due year four changed year-over-year?
- BioCryst Pharmaceuticals's lease liability payments - due year four increased by 59.6% year-over-year, from $996K to $1.59M.
- What does lease liability payments - due year four mean?
- The contractual cash obligations for operating and finance leases due in the fourth year following the balance sheet date. This is part of the long-term lease maturity schedule that helps investors assess the company's future fixed cost burden. It allows for better modeling of long-term capital allocation and cash flow stability.